The company posted adjusted earnings of $2.77 per share on revenue of $21.9 billion, exceeding consensus estimates of $2.59 ...

J&J JNJ began the first-quarter earnings season for the drug and biotech sector with better-than-expected results. J&J’s ...

With broadcasts of the college football and NFL playoffs, as well as the men’s and women’s college basketball tournaments, many drugmakers looked to sports for advertising opportunities in Q1.

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

Johnson & Johnson (J&J) has reported its first-quarter 2025 results, showcasing a 2.4% increase in reported sales to $21.9 ...

The specter of tariffs is likely to overshadow what was a positive quarter for J&J. The company’s adjusted earnings rose 2.2% ...

Johnson & Johnson, a multinational healthcare company, recently reported its first-quarter results for 2025, showcasing ...

Johnson & Johnson (NYSE:JNJ) recently announced a 4.8% increase in its quarterly dividend and released positive Phase 3 clinical data for icotrokinra, an oral treatment for plaque psoriasis. These ...

Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall ...

American healthcare and consumer products giant Johnson & Johnson hiked its annual guidance after a strong start to the year, with the company beating estimates on both the top and bottom lines.